Canadian Cancer Society Funded Research Among Best of Best

03 June 2011

Toronto -

Groundbreaking cancer research funded by the Canadian Cancer Society, took centre stage at the 44th annual meeting of the American Society of Clinical Oncology (ASCO) held June 3 through June 7 in Chicago.

ASCO's Annual Meeting is one of the largest cancer-related conferences in the world bringing together more than 30,000 attendees. Previous years have seen major announcements, including 2005's breakthrough discovery that Herceptin is effective in treating early-stage breast cancer patients.

Twenty seven abstracts describing Society-funded clinical trials were presented at the meeting, including three that have been chosen among the top 1% as "Best of ASCO." Additionally, from among that top 1%, a select few are further chosen to be featured at ASCO press conferences held through the course of the weekend. Typically, it is those few featured studies that are groundbreaking research with the potential to change clinical practice around the world.

The Society funded studies featured at ASCO press conferences are:

MA.20 - Timothy J. Whelan
Highlighted in ASCO Official Press Program and selected for Best of ASCO
NCIC CTG MA.20: An Intergroup Trial of Regional Nodal Irradiation in Early Breast Cancer (Abstract LBA1003)

MAP.3 - Paul E. Goss
Highlighted in ASCO Official Press Program and selected for Best of ASCO
Exemestane for primary prevention of breast cancer in postmenopausal women: NCIC CTG MAP.3 - A randomized placebo-controlled clinical trial. (Abstract LBA504)

PR.7 - Juanita M. Crook
Selected for Best of ASCO
A phase III randomized trial of intermittent versus continuous androgen suppression for PSA progression after radical therapy (NCIC CTG PR.7/SWOG JPR.7/CTSU JPR.7/ UK Intercontinental Trial CRUKE/ 01/013). (Abstract 4514)

 

“It is thrilling that Canadian research is being recognized as a world leader. This type of acknowledgement clearly demonstrates that research funded by the Canadian Cancer Society is resonating within the international healthcare community, specifically for its potential impact,” explains Dr. Michael Wosnick, Vice-President Research, Canadian Cancer Society, and Scientific Director, Canadian Cancer Society Research Institute

This ASCO recognition also further supports the findings of a recent study showing researchers funded by the Canadian Cancer Society are making a bigger scientific impact than other researchers in Canada. The study, an evaluation of the Society’s research grants program, found that researchers funded by the Society publish more papers, publish these papers in the most prestigious scientific journals and are referenced more often by other researchers.

Specifically, the study found that papers published by researchers funded by the Society had a higher scientific impact than papers published by Canadian researchers in all fields. Scientific impact refers to the number of times a published paper is referenced by other papers, as well as the quality of the journal in which papers are published.

“The success of CCS funded studies reflects our world-renowned peer-review system that continues to ensure we support research studies that change cancer treatments for the benefit of patients worldwide,” Wosnick says.

The NCIC Clinical Trials Group is a cooperative oncology group which carries out clinical trials in cancer therapy, supportive care and prevention across Canada and internationally. It is one of the national programs and networks of the Canadian Cancer Society Research Institute, and is supported by the Canadian Cancer Society.

Information concerning this weekend’s press conferences and specific media contacts at ASCO can be obtained here

 

The Canadian Cancer Society is a national community-based organization of volunteers whose mission is the eradication of cancer and the enhancement of the quality of life of people living with cancer. When you want to know more about cancer, visit our website www.cancer.ca or call our toll-free, bilingual Cancer Information Service at 1 888 939-3333.

For more information, please contact:

Christine Harminc

Senior Manager, Communications & Media Relations

Canadian Cancer Society

Phone: 416 934-5340